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Abstract
Background: There are few studies of mortality amongst people who inject drugs (PWID) in Australia. In this study,
we estimate mortality in a cohort of PWID in Melbourne and examine predictors of mortality including health
service use, demographic characteristics, drug use and personal wellbeing.
Findings: We linked identifiers from the Melbourne injecting drug use cohort study (MIX; n = 655) to the National
Death Index from 2008 to 2012 to estimate standardised mortality ratios (SMRs). Cox regression was used to examine
the bivariate relationship between exposures determined at baseline and subsequent mortality. There were 24 (3.6 %)
deaths over the study period. The mortality rate in the cohort was 1.0 per 100 PY (95 % CI 0.71–1.57), with
an SMR of 17.3 (95 % CI 11.6–25.8). Baseline reports of four or more lifetime incarcerations (HR 3.65, 95 % CI 1.16–11.52),
past month ambulance attendance (HR 4.43, 95 % CI 1.76–11.17), past month emergency department presentation
(HR 3.44, 95 % CI 1.47–8.03) and past 6-month self-reported heroin overdose (HR 3.14, 95 % CI 1.24–7.96) were
associated with increased mortality risk.
Conclusions: Contact with emergency services, particularly for drug overdose, remains a lost opportunity to provide
referrals for harm reduction and naloxone training programmes to PWID at greater risk of mortality.
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Introduction
Estimates of mortality among people who inject drugs
(PWID) in developed countries (based mostly on treat-
ment samples [1]) range between 0.5 and 5 deaths per
100 person-years (PY). Stoové et al. [2] reported a mor-
tality rate of 0.8 per 100 PY among PWID in Melbourne
between 1990 and 2006, with most deaths related to
drug overdose and other injecting-related causes; unlike
other countries, HIV mortality was uncommon [3].
A range of factors increase mortality risk among
PWID, including having a history of non-fatal overdose
events [4]. PWID who overdose often come into contact
with ambulance and emergency department (ED) ser-
vices; however, the relationship between the use of these
and other health services with mortality has not been
previously explored.
We provide updated estimates of mortality among
PWID in Australia where HIV prevalence is low and
targeted health services for PWID are available [5]. We
describe the relationship between mortality and demo-
graphic characteristics, patterns of drug use, measures of
personal wellbeing and use of health services.
Methods
Data collection
Baseline data from the Melbourne injecting drug user
cohort study (MIX) collected in Melbourne between No-
vember 2008 and March 2010 was linked to Australia’s
National Death Index (NDI). MIX participants were re-
cruited through a combination of respondent-driven
sampling, snowball sampling and outreach. Eligible par-
ticipants were aged 18 and over, reported injecting regu-
larly for at least 6 months and had a valid Medicare
card. The baseline MIX questionnaire included ques-
tions on socio-demographics, drug use, health service
use, and self-reported health and wellbeing. Further de-
tails of the recruitment methods and the wider study are
described elsewhere [6]. Probabilistic data linkage of
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participant identifier codes based on letters from first
and last names, gender and date of birth was used to
link NDI data, with matches validated using full first
names, deaths known to the study team and date of last
contact. Deaths up to December 2012 were captured
across all states and territories. Cause-of-death codes are
reported where available.
The study was approved by the Human Research Eth-
ics Committee of the Victorian Department of Health
and the Monash University Human Research Ethics
Committee, and informed consent was obtained from all
participants.
Statistical analyses
Person-years (PY) were calculated as the time from
baseline interview until death or censorship at 31st
December 2012. Mortality rates were calculated using
the person-time method [7] and disaggregated by gen-
der. Standardised mortality ratios (SMRs) compared ob-
served age- and sex-specific mortality rates of the cohort
with age- and calendar-year-matched Australian popula-
tion estimates using indirect standardisation. Five-year
age groups were assigned. The 95 % confidence intervals
(CI) were calculated using the Poisson distribution.
Semi-parametric analysis using Cox regression was
used to describe baseline characteristics associated with
mortality, including socio-demographic, drug use and
health service use data. Validated tools included a vari-
ant of the AUDIT-C scale [8] to assess past month alco-
hol consumption (categorised as abstinent, 1–7, 8+) and
the SF8 quality of life scale summary measurements for
physical and mental health [9] as measures of health-
related quality of life (categorised as low (lower quartile
scores), average (second and third quartile scores) and
high (upper quartile scores) [10]). The small number of
events (deaths) restricted analyses to bivariate relation-
ships between exposures and mortality. Variables were
considered significant at p < 0.05. Associations were re-
ported using hazard ratios (HR); 95 % confidence inter-
vals (CIs) for crude mortality rates were calculated using
a Poisson distribution. We describe time-varying factors
associated with mortality using longitudinal data from
the MIX cohort as supplementary analyses to identify
missed opportunities for interventions [2, 7]. Analyses




We recruited 688 participants between 2008 and 2010,
of whom 23 (3.4 %) were excluded from analysis due to
incomplete data on exposures of interest such as past
month use of emergency, outpatient and ambulance ser-
vices. No mortality cases were excluded in this way.
Participants with complete data (n = 665) contributed
2277 PYs across a median of three interviews. Table 1
describes baseline characteristics of participants who
were young relative to other studies of Australian PWID
(median age 29, interquartile range (IQR) 17–40), pre-
dominantly male and unemployed. Participants had been
injecting for a median of 10 years (IQR 6–13) and over a
third were receiving OST. Participants were frequent
users of health services and almost one-third had poor
self-reported physical health.
Mortality rates, causes of death, and correlates of
mortality
There were 24 (3.6 %) deaths in study period; the me-
dian age at death was 28 years (range 19–31) and the
median time from the last interview to death was
257 days (range 7–1134 days). The estimated mortality
rate was 1.0 per 100 PY (95 % CI 0.7–1.6). The esti-
mated SMR was 17.3 (95 % CI 11.6–25.8) overall and
there was no evidence of a significant difference between
women (23.5, 95 % CI 10.5–52.3) and men (15.9, 95 %
CI 10.0–25.3).
Cause of death was available for 23 of the 24: 12 were
drug-related, involving opioids and multiple drug use,
four were suicides, four were due to physical assault,
two were from medical conditions not directly related to
injecting drug use, and one resulted from an accident-
related injury. Heroin was the most common drug de-
tected in the drug-related deaths (83 %), followed by
benzodiazepines (67 %). Most (83 %) drug-related deaths
involved multiple substances, including heroin, benzodi-
azepines, methadone, antidepressants, antipsychotics
and alcohol.
Bivariate Cox regression analyses of associations be-
tween mortality and exposures are presented in Table 1.
Increased mortality risk was associated with frequency
of past incarceration (four or more compared to none),
reporting past month ambulance attendance, reporting
past month ED presentation and reporting a heroin
overdose in the past 6 months. The supplementary ana-
lyses of time-varying exposures showed the same pat-
tern, but some exposures failed to reach significance
(Additional file 1: Table S1).
Discussion
The excess mortality reported in this study was almost
three times higher than previous Australian estimates in-
volving PWID and people on opioid substitution therapy
(OST) [2, 11]. The excess mortality was also higher than
reported in other countries with a low HIV prevalence
[12]. The heightened risk of mortality in this community-
based cohort might be due to systematic differences
beyond injecting drug use. The cohort was community-
recruited rather than treatment-recruited [11] and was
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Table 1 Baseline socio-demographic, risk and health service utilisation factors associated with mortality among PWID in Melbourne
(n = 665)
Characteristics Baseline n (%) Deaths N (%) Hazard ratio (95 % CI) P value
Gender
Male 446 (67.1) 18 (4.0) 1.45 (0.58–3.66) 0.427
Female 219 (32.9) 6 (2.7) 1
Employed
Yes 91 (13.7) 2 (2.2) 0.57 (0.13–2.41) 0.444
No 574 (86.3) 22 (3.8) 1
Stable accommodation
Yes 539 (81.0) 22 (4.1) 2.53 (0.59–10.77) 0.209
No 126 (18.9) 2 (1.6) 1
Current OST
Yes 236 (35.5) 8 (3.4) 0.92 (0.39–2.16) 0.854
No 429 (64.5) 16 (3.7) 1
Attended emergency department
in the past month
Yes 88 (13.2) 6 (12.0) 3.44 (1.47–8.03)* 0.004
No 577 (86.8) 18 (2.9) 1
Attended PWID specific primary
care services in the past month
Yes 116 (17.4) 22 (4.0) 0.43 (0.10–1.82) 0.249
No 549 (82.6) 2 (1.7) 1
Attended GP services in the past
month
Yes 387 (58.2) 16 (4.1) 1.44 (0.61–3.36) 0.403
No 278 (41.8) 8 (2.9) 1
Attended ambulance services in
the past month
Yes 50 (7.5) 6 (12.0) 4.43 (1.76–11.17)* 0.002
No 615 (92.5) 18 (2.9) 1
Past week heroin injecting
frequency
None 10 (25.6) 6 (3.5) 1
Less than daily 297 (44.7) 12 (4.0) 1.14 (0.43–3.04) 0.794
Daily or more 198 (29.8) 6 (3.0) 0.84 (0.27–2.60) 0.760
AUDIT Alcohol Consumption
Questions score
Abstinent 239 (35.9) 9 (3.8) 1
1–7 264 (39.7) 7 (2.6) 0.69 (0.26–1.87) 0.472
8 + 162 (24.4) 8 (4.9) 1.35 (0.52–3.50) 0.537
Arrested in the past 12 months
Yes 359 (54.0) 17 (4.7) 2.11 (0.88–5.09)† 0.096
No 306 (46.0) 7 (2.3) 1
Frequency of past incarceration
None 271 (40.7) 7 (2.6) 1
3 or less 339 (51.0) 12 (3.5) 1.39 (0.55–3.52) 0.491
4 or more 55 (8.3) 5 (9.1) 3.65 (1.16–11.52)* 0.027
Nambiar et al. Harm Reduction Journal  (2015) 12:55 Page 3 of 5
relatively young compared to other cohorts [2, 11]. The
excess mortality is comparable to results in contemporan-
eous cohorts of similar age [7], and the mortality rate
might converge to estimates in the wider literature over a
longer observation period potentially reflecting changes in
risk behaviour with age and retention in drug treatment
observed in other studies [11, 13].
The mortality rate reported here is comparable to that
in a recent Australian cohort of PWID recruited from
prison settings and followed post-release [14]. Over half
the MIX cohort reported a history of incarceration at
baseline and we found that frequent incarceration was
associated with mortality. Multiple events of incarcer-
ation indicate a particularly vulnerable group with an
over-representation of low levels of education and socio-
economic status, and unsafe injecting practices [15]. The
primary overdose prevention tools potentially available
through the criminal justice system are the pre- to post-
release continuation of OST and the provision of nalox-
one at prison release. The impact of such programmes
can be enhanced through a continuum of care between
prison and community health services that facilitates
programme retention.
Ambulance and ED attendance reported in the month
prior to the last interview were associated with increased
risk of mortality, as was reporting a heroin overdose in
the previous 6 months. For three of the five deaths for
which a previous ambulance attendance was reported,
the attendance related to an overdose (data not shown).
Frequent contact with emergency and ambulance
services could be used to identify PWID at greater risk
of fatal overdoses. Multiple overdose events may indicate
reduced tolerance, interactions with other substances
and the presence of other comorbidities [16]. Contact
with emergency services is an opportunity to provide
targeted harm reduction initiatives, such as take-home
naloxone.
Limitations
Our study was limited by a small number of mortality
events which affected the precision of estimates and lim-
ited adjusted mortality models. In most cases there was
only a short observation period available for participants
who died which limited our ability to observe the effect
of time-varying risk factors, although this strengthens
the temporal relevance of the observations in relation to
mortality. The quality of the linkage was dependent on
the accuracy of participant-provided identifier data. Ex-
posures in cohort studies such as this are assumed to be
fixed between interviews or censorship; however, this as-
sumption is not always valid and means the predictors
of mortality reported here should be interpreted with
caution.
Conclusions
This analysis of mortality in community-recruited
Australian PWID found significantly higher excess mor-
tality than previous Australian studies and studies in
comparable developed countries. These results highlight
the importance of tailored interventions prioritising
Table 1 Baseline socio-demographic, risk and health service utilisation factors associated with mortality among PWID in Melbourne
(n = 665) (Continued)
Duration of injecting career (years)
Less than 3 77 (11.6) 4 (5.2) 1
3–9 243 (36.5) 8 (3.3) 0.63 (0.19–2.09) 0.450
Greater than 10 345 (51.9) 12 (3.5) 0.67 (0.22–2.08) 0.491
Overdose in the past 6 months
Yes 10 (1.5) 6 (9.2) 3.14 (1.24–7.96)* 0.016
No 655 (98.5) 18 (3.0) 1
SF8 physical health score in the
past month
High (>56) 161 (24.1) 4 (2.5) 1
Average (45–56) 330 (49.6) 10 (3.0) 1.23 (0.39–3.93) 0.725
Low (<45) 174 (26.2) 10 (5.7) 2.39 (0.75–7.63)† 0.140
SF8 mental health score in the
past month
High (>53) 181 (27.2) 8 (4.4) 1
Average (31–53) 327 (49.2) 9 (2.7) 0.63 (0.24–1.64) 0.344
Low (<31) 157 (23.6) 7 (4.5) 1.03 (0.37–2.85) 0.949
*p < 0.05
†p < 0.1
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overdose prevention to young PWID. Our findings point
to prison and emergency settings as ideal opportunities to
deliver interventions such as harm reduction messages
and referrals for naloxone training and prescribing to
reduce mortality [17].
Highlights
 We describe mortality in a cohort of young,
community-based Australian PWID
 Excess mortality in the cohort was higher than other
local estimates and settings where HIV prevalence is
low
 Recent use of emergency services such as emergency
departments and ambulances was associated with
mortality
 Opportunities remain in prisons and emergency
settings to deliver overdose-related interventions
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